The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending booster shots.

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about $29 million upfront.

Two studies published in Nature found stem-cell derived products can not only be safely transplanted into the brain, but also ...

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

The advisory committee, which met Tuesday for the first time since Robert F. Kennedy Jr. was sworn in as health secretary, ...

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

This blog delves into the rise of rare disease drug approvals and the critical importance of regulatory guidance in shaping ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz is alleging Amgen's patent actions were anticompetitive.

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...